We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Five-year remission without disease progression in a patient with relapsed/refractory multiple myeloma with extramedullary disease treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study: a case report.
- Authors
Wang, Bai-Yan; Zhao, Wan-Hong; Chen, Yin-Xia; Cao, Xing-Mei; Yang, Yun; Zhang, Yi-Lin; Wang, Fang-Xia; Zhang, Peng-Yu; Lei, Bo; Gu, Liu-Fang; Wang, Jian-Li; Bai, Ju; Xu, Yan; Wang, Xu-Geng; Zhang, Rui-Li; Wei, Li-Li; Zhuang, Qiu-Chuan; Fan, Frank; Zhang, Wang-Gang; He, Ai-Li
- Abstract
Background: Multiple myeloma remains incurable despite treatment advancements over the last 20 years. LCAR-B38M Cells in Treating Relapsed/Refractory Multiple Myeloma was a phase 1, first-in-human, investigator-initiated study in relapsed/refractory multiple myeloma conducted at four sites in China. The study used LCAR-B38M chimeric antigen receptor-T cells expressing two B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity, and a CD3ζ signaling domain with a 4-1BB costimulatory domain to optimize T-cell activation and proliferation. This chimeric antigen receptor construct is identical to ciltacabtagene autoleucel. In the LEGEND-2 study (n = 57, Xi'an site), overall response rate was 88%; median (95% CI) progression-free survival and overall survival were 19.9 (9.6–31.0) and 36.1 (26.4–not evaluable) months, respectively; and median follow-up was 25 months. This case study reports on a patient with relapsed/refractory multiple myeloma (λ light chain type) who was treated with LCAR-B38M chimeric antigen receptor T cells in the LEGEND-2 study (Xi'an site); he had received five prior lines of treatment and had extensive extramedullary lesions. Case presentation: The patient, a 56-year-old Asian male, received cyclophosphamide (500 mg daily × 3 days) as lymphodepletion therapy and a total dose of 0.5 × 106 chimeric antigen receptor + T cells/kg split into three infusions (days 1, 24, and 84 from June to August 2016). He experienced grade 2 cytokine release syndrome after the first infusion; all symptoms resolved with treatment. No cytokine release syndrome occurred following the second and third infusions. His λ light chain levels decreased and normalized 20 days after the first infusion, and extramedullary lesions were healed as of January 2018. He has sustained remission for 5 years and received no other multiple myeloma treatments after LCAR-B38M chimeric antigen receptor T cell infusion. As of 30 October 2020, the patient is still progression-free and has maintained minimal residual disease-negative (10–4) complete response status for 52 months. Conclusions: This case provides support that treatment with LCAR-B38M chimeric antigen receptor T cells can result in long-term disease remission of 5 or more years without disease progression in a heavily pretreated patient with extensive extramedullary disease and no other treatment options.
- Subjects
XI'AN Shi (China); CHINA; CHIMERIC antigen receptors; EXTRAMEDULLARY diseases; PLASMACYTOMA; DISEASE remission; DISEASE progression; CYTOKINE release syndrome
- Publication
Journal of Medical Case Reports, 2022, Vol 16, Issue 1, p1
- ISSN
1752-1947
- Publication type
Case Study
- DOI
10.1186/s13256-022-03636-9